The purpose of this study was to examine the reliability and validity of a Spanish version of the Beliefs about Medicines Questionnaire (BMQ) as a measure to evaluate beliefs about medications and to differentiate adherent from nonadherent patients among low-income Latino patients with diabetes in the United States.
Construct validity testing shows nearly identical factor loading as the original construct map. General Overuse scores were significantly more negative for patients reporting each reason for nonadherence compared with their adherent counterparts. Necessity-Concerns difference scores were significantly more negative for patients reporting nonadherence for reasons other than cost compared with those who did not report this reason for nonadherence.
Introduction
Adherence to a medication regimen is central to the proper management of chronic health conditions, in general, and is critical to improving glycemic control and preventing complications for individuals with diabetes, specifically. [1] [2] [3] [4] However, adherence to medications is not a simple task, considering its multifactorial nature. 5 Studies have reported a variety of factors that may lead a patient to be nonadherent, including increasing costs of medications, 6 shared or personal beliefs about the potential harms of medications, 7 and lack of social support. [7] [8] [9] [10] Such barriers to adherence are especially taxing on patients from low socioeconomic backgrounds, 7, 11, 12 most likely due to a lack of resources to support disease management. Latinos, particularly immigrants of Mexican descent, have lower levels of socioeconomic status and decreased levels of access to health insurance in comparison with their non-Hispanic white counterparts. 13 Understanding barriers to medication adherence may improve health outcomes for ethnically diverse patients with chronic illness.
Central to improving medication adherence is the understanding of a patient's reasons for nonadherence. 14 Existing measures of nonadherence can identify patients who exhibit unintentional nonadherence (due to forgetfulness or difficulty getting to the pharmacy), 15 intentional nonadherence due to cost, 16 or intentional nonadherence due to reasons other than cost (concerns about side effects or a lack of benefit from the medication). 16, 17 Unintentional nonadherence could possibly be remedied through automated reminders, social support, or mail-order refills. [18] [19] [20] Likewise, intentional nonadherence due to cost can be reduced by lowering the out-of-pocket costs of medications. 21, 22 Intentional nonadherence due to reasons other than cost, however, can be difficult to address as many patients do not communicate these negative beliefs to their health providers. [23] [24] [25] For this reason, identifying patients with negative beliefs about medications may help providers address these concerns and prevent future nonadherence, especially for the many patients who never initiate a newly prescribed medication 26 or discontinue the medications soon after starting. 27 The Beliefs about Medicines Questionnaire (BMQ) has been used to identify patients with negative beliefs about medications that may lead to nonadherence. 28, 29 The BMQ has been administered in various patient populations with different diagnoses, including chronic conditions such as asthma, hypertension, and HIV, [30] [31] [32] and across diverse cultural groups. 33 Although the BMQ has been translated into Spanish and validated in previous studies conducted in Spain, [34] [35] [36] it has not yet been validated for use with Spanish-speaking Latino patients with diabetes living in medically underserved communities within the United States. Because negative beliefs about medications are an important contributor to nonadherence in this population, 7 this study aims to assess the reliability and validity of a Spanish translation of the BMQ to (1) evaluate patient beliefs about medications and (2) discriminate adherent from nonadherent patients among low-income, Latino adults with diabetes living in the United States.
Methods Design
The present study is a cross-sectional observational study of a subset of patients participating in the EMPATHy Toolkit randomized clinical trial. 37 
Setting and Sample

Parent study
The sample for the current study consisted of a subset of participants in a larger parent study, described in detail elsewhere. 37 In short, participants for the parent study were recruited from a university-affiliated federally qualified health center in Santa Ana, California, that predominantly serves low-income, ethnic minority patients, mostly of Hispanic ethnicity. Patients who met the following criteria were recruited: (1) age 18 years and older; (2) poorly controlled type 2 diabetes (as indicated by A1C > 7.5% [53 mmol/mol], LDL cholesterol > 100 mg/dL [2.59 mmol/L], or systolic blood pressure > 140 mmHg), (3) Hispanic ethnicity, and (4) English or Spanish speaking. Two hundred eighty-five eligible patients were approached before their regularly scheduled diabetes appointments. Of these, 210 (73.7%) consented to participate in the parent study.
BMQ validation subset
A subset of participants (the "BMQ validation subset"), recruited consecutively at the end of the parent study (n = 73), was asked to complete an additional questionnaire about their medication-related beliefs (BMQ) and adherence behaviors. Participants in this BMQ validation subset make up the analytic sample for this study.
Measures
Participants in the BMQ validation subset were asked to complete a Spanish language version of the BMQ, adapted from a version developed and validated for use in Spain in a previous study, 35 during the baseline visit, in addition to measures collected as part of the parent study protocol.
The BMQ
The BMQ is an 18-item questionnaire consisting of 2 sections-the BMQ General, which assesses the patient's beliefs about medications in general, and the BMQ Specific, which assesses beliefs about the patient's specific medications. 38 The questionnaire has been used and validated in numerous clinical studies since then, including those investigating nonadherence in patients with diabetes. [38] [39] [40] [41] The BMQ General examines a person's ideas about medicines in general and consists of 2 subscales: General Overuse and General Harm. The BMQ Specific, on the other hand, focuses on a person's ideas about specific medicines that are prescribed for personal use and also consists of 2 subscales: Specific Necessity and Specific Concerns.
In this study, responses to the BMQ items were collected using a Likert-type scale from 1 to 5, allowing the study participants to choose where they lie in agreement with each of a series of statements (1 means strongly agree, whereas 5 means strongly disagree). The responses from each subscale were reverse coded as needed and averaged so that higher scores correspond with a higher endorsement of beliefs described by the scale. Furthermore, following the Necessity-Concerns Framework posited by Horne and colleagues, 33 the difference between Specific Necessity and Specific Concerns subscale scores was calculated for each patient to evaluate the patient-perceived benefit-cost analysis of medications.
Prior to data collection, the Spanish language items from a version of the BMQ that was previously validated in Spain 35 were reviewed for reading level and idiomatic compatibility with Latin American Spanish by a research staff member who is a native speaker of Latin American (Mexican) Spanish and is experienced working with Spanish-speaking patients in medically underserved communities in the United States. Items for which the translation was not deemed appropriate for the target population were retranslated from English into Latin American Spanish by the staff member and back-translated for verification by a second native Latin American (Mexican) Spanish speaker on the study team. The adapted questionnaire is compared with the original English version in Table 1 .
Characterization of nonadherence behaviors
A brief baseline survey was administered to all participants prior to the study intervention. It included a 15-item questionnaire that asked about medication nonadherence behaviors within the past 3 months prior to the study visit. The questionnaire was adapted from a measure used in a national survey of Medicare beneficiaries 16 that has been used in previous research on contributors to suboptimal diabetes outcomes in low-income Latino patients. 7, 42 Such responses were then used to characterize the nonadherence behaviors into 3 main types: (1) cost-related nonadherence; (2) nonadherence due to reasons other than cost, such as doubts about the medications' effectiveness or concerns about side effects; and (3) unintentional nonadherence, such as forgetting to take their medication.
Out-of-pocket costs
The patient's total monthly out-of-pocket costs for medications were assessed using a single question: "On average, how much do you spend on your medications per month?"
Statistical Analysis
All statistical analyses were performed using SPSS version 23.0 (IBM Corporation, Armonk, New York). Participant characteristics were compared between adherent and nonadherent groups using univariate statistics. Internal consistency was assessed via the Cronbach's alpha for each BMQ domain. The construct validity of the BMQ was then evaluated using a confirmatory factor analysis with a 2-factor structure for each of the BMQ sections, which replicated the original BMQ validation study. 38 Finally, the convergent and discriminate criterion validity was tested by comparing BMQ mean scores and out-of-pocket medication costs for patients who did and did not report each type of nonadherence behavior. Specifically, it was posited that the convergent and discriminant criterion validity of the measures would be supported by the following pattern of associations (summarized in Table 2 ):
1. Patients exhibiting any type of nonadherence (unintentional, intentional related to cost, and intentional for reasons other than cost) would report more negative beliefs on 
Results
Characteristics of the BMQ Validation subset sample (N = 73) are described in Table 3 . Of these patients, 61% reported unintentional nonadherence, 75% reported intentional nonadherence for reasons other than cost, and 26% reported cost-related nonadherence.
Internal Consistency
The internal consistency of this Spanish version of the BMQ was examined to assess whether items under a particular construct produce similar scores to one another. The Cronbach's alpha was found to be .678 for the BMQ Specific and .774 for the BMQ General scales. The Cronbach's alpha for the subdomains of the BMQ General were .786 and .694 for General Overuse and General Harm, respectively.
Construct Validity
The construct validity of the BMQ in a Latino, Spanish-speaking population in Southern California was assessed through confirmatory factor analysis. The original measure development study 38 used exploratory factor analysis of 34 novel items to identify the factor structure that informed the selection of the final 18 items that make up the BMQ and guided the grouping of those items into the 4 BMQ subscales. Then, in the present study, confirmatory factor analysis of the Spanish translation of this measure was performed to examine whether this original factor structure of the BMQ was retained in the responses of US-dwelling, Spanish-speaking Latino patients with diabetes. Table 4 contains the 2-factor structure of the 10-item BMQ Specific. Each item loaded onto a single factor and did not display split loading. All 5 of the Specific Necessity items loaded onto factor 1. Similarly, all 5 of the Specific Concerns items loaded onto factor 2. This 2-factor structure accounted for 48.6% of the total variance explained for the components of the BMQ.
Similarly, Table 5 shows the 2-factor structure of the 8-item BMQ General. For the General Overuse subdomain, 3 items loaded onto factor 1. The 4 General Harm items loaded onto factor 2. Thus, most items of the BMQ General loaded appropriately. Only item 4, "Natural remedies are safer than medications," demonstrated split loading between factors 1 and 2. This 2-factor structure accounted for 59% of the total variance explained for the components of the BMQ. 
Criterion Validity
Criterion validity was examined by comparing the mean scores of the BMQ subscales between adherent and nonadherent patients for each adherence outcome. Figure 1 shows the results of the independent samples t tests comparing the General Overuse mean score (Figure 1a) , General Harm mean score (Figure 1b) , Specific Necessity-Concerns difference score (denoted as Sn-Sc; see Figure 1c ), and mean monthly out-of-pocket cost of medications (Figure 1d ) for adherent versus nonadherent patients for each type of nonadherence. General Overuse mean scores are higher in the groups that demonstrated unintentional nonadherence (P = .003), nonadherence not due to cost (P = .001), and costrelated nonadherence (P = .001) compared with their counterparts who reported adherence to their medications. General Harm scores did not differ between adherent and nonadherent patients for any adherence outcome. There is a significant difference in Sn-Sc score in patients who reported nonadherence not due to cost versus those who reported adherence (mean ± SD = .77 ± .90 vs 1.30 ± 1.03; P = .04). In addition, out-of-pocket monthly cost of medications differed between those who reported cost-related nonadherence and those who did not (mean ± SD = $78.58 ± $80.17 vs $29.39 ± $61.56; P < .001).
Discussion
This study assessed the validity and reliability of the BMQ in a patient population of Spanish-speaking Latinos with uncontrolled diabetes. The results of this study showed that the Spanish language 18-item BMQ is reliable in this study population, as evidenced by acceptable Cronbach's alpha scores. The factor structure of the translated items is comparable with the original concept map proposed by Horne et al 38 and supports the construct validity of the measure in this population. Furthermore, the results of the criterion validity testing demonstrate that the domains of the BMQ are able to predict certain types of nonadherence outcomes and therefore may be useful in targeting patients who may be at risk of medication nonadherence.
Internal consistency testing demonstrated fair to moderate Cronbach's alpha values (.678-.786). These values are consistent with other studies that have tested the BMQ in other patient populations. 28, 43, 44 Thus, it can be concluded that the BMQ is a useful and reliable measure of patient beliefs about medications, including for a Spanish-speaking Latino population.
Confirmatory factor analysis of the BMQ demonstrated adequate factor loading for both domains. For the BMQ Specific in particular, the items that loaded onto factors 1 and 2 are well represented by the established constructs of Specific Necessity and Specific Concerns, respectively. The items of the BMQ General, conversely, did not load as strongly. The items that loaded onto factors 1 and 2 most likely represent General Overuse and General Harm, respectively; however, the factor analysis demonstrated split loading of the item "Natural remedies are safer than medicines."
This deviation from the original concept map may be explained in part by cultural variations in usage of natural therapies. According to the 2002 National Health Interview Survey, Hispanics were the second largest ethnic group to report the use of complementary and alternative medicine (CAM). Hispanic older adults in particular had greater odds of using CAM compared with their white counterparts. 45 Increased likelihood of use of CAM may reflect greater trust in natural remedies, which can in turn translate into mixed beliefs regarding the usage of allopathic medications, thus skewing the construct validity of this particular item. Overall, however, the factor analysis of the Spanish BMQ demonstrated valid measurement of the constructs, signifying that the BMQ scores can provide accurate information regarding the nature of the beliefs that affect medication adherence. The intention of the criterion validity testing was to evaluate the accuracy of the BMQ scores to reflect an established measure of medication nonadherence. 16 According to the hypotheses of this study, if the Spanish BMQ were valid, stronger negative beliefs toward medications (defined by low Specific Necessity mean scores or high Specific Concerns, General Overuse, and General Harm mean scores) would correlate highly with the presence of nonadherence behaviors. Particularly, the results of the criterion validity testing demonstrate that the General Overuse subdomain was significantly associated with all 3 of the nonadherence behaviors. In other words, patients who reported nonadherence behaviors had greater mean General Overuse scores compared with patients who reported adherence to their medications. Contrary to the study hypotheses, the General Harm measure did not discriminate adherent from nonadherent patients on any of the nonadherence measures.
In addition, the Specific Necessity-Concerns difference score was significantly associated with intentional nonadherence due to reasons other than cost. Patients who reported nonadherence for other reasons had a narrower difference between the Specific Necessity and Specific Concerns mean scores. This implies that patients who believed that the risks of taking their medications (ie, concerns) outweighed the benefit (ie, necessity) were more likely to report intentional nonadherence due to reasons other than cost. This is consistent with the current literature, particularly in reference to the NecessityConcerns Framework, which contextualizes the effect of this risk-benefit analysis on medication adherence. According to a meta-analysis inclusive of 94 studies that used the BMQ, higher adherence was associated with stronger perceptions of necessity of treatment and fewer concerns about medications. 33 Furthermore, as a reference for the criterion validity testing, out-of-pocket monthly cost of medications was compared across adherence categories for all 3 forms of nonadherence. As expected, the results demonstrated that cost was significantly associated with cost-related nonadherence. Patients who reported cost-related nonadherence paid on average $50 more per month for their medications than their adherent counterparts. A systematic review by Briesacher et al 46 reported an established link between medication adherence and cost, particularly in the presence of underlying financial burden. This review also revealed that heavy disease burden is also a contributing factor toward nonadherence. 46 Therefore, a possible next step for this measurement study would be to evaluate the effect of disease severity and patient-perceived burden on nonadherence behaviors, cost, and BMQ scores.
There are several limitations to this study. First, data were collected using a single cross-sectional survey. Therefore, a causal relationship between long-term beliefs and perceptions of medications cannot necessarily be inferred. For example, it is unclear if beliefs about medications lead to nonadherence or nonadherent behaviors persuade patients to alter their beliefs. Second, the focus of the study is to assess beliefs about medication adherence and not other adherence behaviors that are also critical for diabetes management, such as diet and exercise modifications. Third, the results are based on selfreported nonadherence, which is subjective by nature. For future studies, more objective measures of medication adherence, such as medication electronic monitoring system (MEMS) bottle caps that record each time a medication bottle is opened, 5 can be used. Fifth, because the study population consisted of Latino, Spanish-speaking patients with diabetes living in the United States, the results may not generalize to other populations.
Finally, although the content validity (ie, the extent to which the measure represents all relevant facets of a construct) of the original BMQ was established through the item-generation process described in the original measure development study, 38 the content validity was not formally re-evaluated in the present study. Instead, consistent with other studies demonstrating the reliability and validity of the BMQ in novel populations and languages, [34] [35] [36] the study provides evidence for the internal consistency, construct validity and criterion validity to guide other investigators' evaluations of the BMQ for use in US-dwelling Latinos with diabetes. It is possible, however, that additional tailoring of the item content may further improve the performance of the measure in this population.
Implications for practice
The BMQ has been used extensively in clinical practice to predict adherence. [30] [31] [32] [33] It is a practical and useful instrument that can help guide the patient-clinician discussion regarding disease management and can facilitate the communication of concerns that the patient may have regarding taking medications. 33 In this sense, the BMQ is effective in identifying patients at risk of medication nonadherence in order to further provide support and intervention. The assessments of validity and reliability that were employed in this study suggest that the measure is appropriate for use in Latino patients with diabetes living in medically underserved communities in the United States.
Studies on medication adherence and barriers to treatment are particularly lacking for minority and underrepresented patient populations, especially those who speak a language other than English. 35 Health beliefs-whether they are shared among community members or held only by the individual-have critical implications on an individual's disease management and perceptions of medication use. The findings from this study suggest that the beliefs that medications are overused in general may contribute to multiple types of nonadherence behavior and support the well-documented finding that higher outof-pocket costs contribute to cost-related nonadherence. 22 An additional, important implication of the findings is that negative beliefs about the tradeoff of benefits to harms about a specific medication may contribute to nonadherence for reasons that cannot be addressed simply by reducing out-of-pocket costs. These negative beliefs can be measured reliably in a high-risk population of Latino patients with diabetes living in medically underserved communities the United States and may represent an important target for intervention to reduce disparities in diabetes outcomes.
Just as providers can anticipate-and attempt to mitigate-cost-related nonadherence when prescribing expensive medications or unintentional nonadherence for patients with complex regimens or limited support, measures like the BMQ may be useful to help providers anticipate intentional nonadherence for reasons other than cost and take steps to engage patients in a discussion about those beliefs. The findings support the need for future research to better understand culturally-bound beliefs about medications and to develop interventions aimed to promote more positive beliefs about medications in underserved Latino patient populations with great potential to benefit from optimal therapy.
